Abstract The regulatory effects of the immune system on the skeleton during homeostasis and activation have been appreciated for years. In the past decade it has become evident that bone tissue can also regulate immune cell development. In the bone marrow, the differentiation of hematopoietic progenitors requires specific microenvironments, called ''niches,'' provided by various subsets of stromal cells, many of which are of mesenchymal origin. Among these stromal cell populations, cells of the osteoblast lineage serve a supportive function in the maintenance of normal hematopoiesis, and B lymphopoiesis in particular. Within the osteoblast lineage, distinct differentiation stages exert differential regulatory effects on hematopoietic development. In this review we will highlight the critical role of osteoblast progenitors in the perivascular B lymphocyte niche.
B-Lymphocyte Development is Dependent upon Growth Factors and Cytokines Provided by the Stromal Microenvironment
In mammals B-lymphocyte development occurs in the fetal liver during embryonic development, then migrates to the bone marrow (BM) in the perinatal period, where B lymphocytes are continually generated throughout the life span [1] . The successful development of lymphoid precursors into committed B cells expressing antigen-specific receptors requires signals from the specialized microenvironment constituted by nonlymphoid stromal cells that interact intimately with the developing lymphocytes, providing paracrine support by producing humoral factors such as cytokines and growth factors and physical support by cellsurface molecular interactions. These stromal cell subsets participate in the establishment of specific BM microenvironments, also called ''bone marrow niches,'' required for the generation and maintenance of B lymphopoiesis and hematopoiesis in general.
Each step during B-cell differentiation is regulated by growth factors and cytokines as well as by cell-cell contact [2] . Within the BM, B-lymphocyte development begins with the differentiation of hematopoietic stem cells (HSCs) into common lymphoid progenitors, which in turn give rise to the earliest identifiable B-cell precursors, prepro-B cells. Prepro-B cells progressively differentiate into intermediate pro-B and pre-B cell stages, followed by immature/naive IgM ? B cells and finally by terminally differentiated antibody-secreting plasma cells [3] [4] [5] [6] [7] [8] .
The progression of B-lymphocyte development within the BM is critically dependent upon the actions of various cytokines, particularly chemokines and interleukins, which act at specific steps of differentiation. Gene targeting studies have revealed that among the chemokines CXCL12 and its receptor CXCR4 are essential for B-cell development. Experimental deficiency of CXCL12 or CXCR4 in the developing murine embryo results in early lethality dueimpaired B lymphopoiesis and BM myelopoiesis [9] [10] [11] [12] [13] . Interleukin (IL)-7 has also been shown to be a critical cytokine for lymphoid development and, in particular, to be essential for differentiation of pro-B cells. However, IL-7 is ineffective as a regulator of the differentiation of B-lineage cells beyond pre-B-cell development since more mature B lymphocytes lack the IL-7 receptor [14] [15] [16] . Both IL-7 and IL-7 receptor knockout (KO) mice exhibit an arrest in B-cell development at the pro-B cell stage in BM [16, 17] .
These supporting cytokines are supplied to hematopoietic progenitors by a network of nonhematopoietic stromal cells, and distinct populations of stromal cells appear to play key roles at unique stages of differentiation. Tokoyoda et al. [2] localized prepro-B cells in close contact to CXCL12-expressing stromal cells in vivo. Stromal CXCL12-expressing cells have been described as having a reticular morphology and are dispersed throughout BM in particular surrounding sinusoidal endothelial cells [2, 18] . In contrast, mitotically active pro-B cells are found near IL-7-expressing cells, which are distinct from both CXCL12-expressing cells and bone-lining osteoblasts [2] . IL-7-expressing cells are also closely apposed to the vasculature [19] . As B-cell precursors mature further into pre-B cells, however, they are found at some distance from both CXCL12 and IL-7-expressing stromal cells [2] . A specific niche constituted by galectin-1-expressing stromal cells, distinct from IL-7-expressing cells, has been reported for pre-B cells [19] [20] [21] . Finally, naive IgM ? B cells enter the blood circulation and complete their differentiation in peripheral lymphoid organs. Of note, terminally differentiated B lymphocytes, or antibody-producing plasma cells, return to the BM, where they are found in contact with the cell bodies and processes of CXCL12-expressing cells and perivascular dendritic cells [22] . These findings demonstrate that B-cell precursors migrate between specific niches during the course of differentiation and that these niches are comprised of distinct populations of stromal cells.
The Importance of Bone to Hematopoiesis and B Lymphopoiesis
Beyond B lymphocytes, specific niches have been identified in the BM for HSCs (reviewed elsewhere in this issue by Link and Calvi [23] ) as well as maturing lineage-committed precursors, including those that will give rise to neutrophils and platelets [24, 25] . The cellular identity of the stromal cells supporting these various stages of hematopoiesis is of significant interest. In the BM, the stroma is composed of a heterogeneous group of cells-many are of mesenchymal origin, including fibroblasts, osteoblasts, adipocytes, reticular cells, endothelial cells, and perivascular cells; but sympathetic neurons, glial cells, and macrophages have also been shown to be part of the supportive microenvironment [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . In this review we will highlight the role of cells of the osteoblast lineage, increasingly recognized as essential for supporting B lymphopoiesis at various stages in the BM [36, 37] .
Hematopoietic BM is contained in bones, and therefore, osteoblastogenesis is necessary for bone formation and subsequent BM development. In mice lacking either Runx2 or Osterix, transcription factors required for osteoblast development, the absence of bone tissue and the resulting failure of BM formation result in the outsourcing of hematopoiesis to extramedullary organs [38] [39] [40] [41] [42] . With respect to B-lymphocyte differentiation, a crucial role for the osteoblast lineage was revealed by ablation of osteoblasts in vivo. In transgenic mice with thymidine kinase targeted to maturing osteoblasts by the 2.3-kb type I collagen promoter, ablation of osteoblasts by administration of ganciclovir resulted in decreased BM cellularity with an acute loss of B lymphocytes, followed by progressive loss of HSC subsets [43] . Zhu et al. [44] further demonstrated that calvarial osteoblasts in culture could support the full differentiation program of hematopoietic stem/progenitor cells into the B-lymphocyte lineage, confirming a direct interaction between osteoblastic cells and B-cell precursors.
Cells of the Osteoblast Lineage at Differing Stages of Differentiation Serve Distinct Functions in the BM Hematopoietic Niche
The osteoblast lineage itself is quite heterogeneous, representing a spectrum of differentiation stages from newly committed osteoblast progenitors (hereafter referred to as ''osteoprogenitors'') to terminally differentiated osteoblasts. Commitment to the osteoblast lineage from mesenchymal stem cells begins with the expression of Runx2, a transcription factor required for osteoblastogenesis [38, 39, 45] . Downstream of Runx2, osteoblast commitment is reinforced by expression of Osterix (Osx), which is expressed in proliferative osteoprogenitors [40] . Differentiation of the osteoblast lineage is marked by the progressive expression of markers of osteoblast maturation: alkaline phosphatase, type I collagen, bone sialoprotein, osteopontin, and osteocalcin [46] .
With such a diversity of populations within the osteoblast lineage, it is likely that cells at various stages of differentiation will serve unique functions in the hematopoietic niche. Indeed, increasing evidence suggests that earlier stages of the osteoblast lineage are especially crucial to hematopoietic support. Mice lacking either Runx2 or Osx fail to develop a mineralized skeleton and die soon after birth with a complete absence of BM inside the long bones [38, 39, 41] . In contrast, mice deficient in osteocalcin, a marker of terminally differentiated osteoblasts, are phenotypically normal with stronger bones and greater mineral density than their control littermates and no hematopoietic alterations reported [47] .
In vitro studies have also shown that the maturational status of osteoblasts influences their hematopoietic supporting ability. In cocultures with hematopoietic stem/progenitor cells, freshly isolated calvarial osteoblasts, which expressed higher levels of immature osteoblast markers, were better able to support hematopoietic expansion than calvarial osteoblasts that had been previously cultured and expressed markers of mature osteoblasts [48] . In follow-up studies this group demonstrated that expression of CD166 on cultured osteoblasts correlated with high levels of Runx2 expression, low levels of osteocalcin expression, and high hematopoiesis-enhancing activity. Furthermore, loss of CD166 expression with osteoblast differentiation and maturation was associated with loss of support for hematopoietic function [49] . Consistent with the idea that earlier stages of the osteoblast lineage are more relevant to the hematopoietic niche, the CD105
? Thy1 -fraction of fetal mesenchymal progenitors can direct formation of a hematopoiesis-supporting microenvironment when transplanted under the renal capsule. In contrast, the CD105
? Thy1 ? fraction, enriched in more committed osteoblast-lineage cells, can form only ectopic bone lacking a hematopoietic marrow [50] .
Mesenchymal Progenitors are Perivascular and Support B Lymphopoiesis
Mature osteoblasts are easily identified in situ on bone surfaces by their cuboidal morphology. Upon terminal differentiation, osteoblasts may remain on the bone surface as flattened, quiescent lining cells; be incorporated into mineralized matrix as osteocytes; or die by apoptosis [51] . In contrast to mature osteoblasts and osteocytes, however, earlier mesenchymal progenitors and osteoblast precursors have been more difficult to identify within the nonhematopoietic stroma in vivo. The absence of specific surface antigen markers capable of unequivocally distinguishing the different stromal subpopulations and their stages of maturation has been a challenge in the field. In BM and other tissues, mesenchymal stem cells share features with perivascular cells, termed ''pericytes'' [52, 53] . Recently, perivascular cells variously described as expressing PDGFRa and Sca-1, Nestin, the leptin receptor, or Prx1 and exhibiting multipotent mesenchymal capacity have been identified as crucial components of the HSC niche [29, [54] [55] [56] [57] .
While the perivascular niche does not contain mature osteoblasts, growing evidence suggests that osteoprogenitors are also perivascular. During embryonic development Osxexpressing osteoprogenitors, but not type I collagenexpressing osteoblasts, are found in close proximity to invading blood vessels [58] . In humans and rodents, expression of CD146 marks a population of reticular cells lining the sinusoids of the BM microvasculature that express alkaline phosphatase and can be induced to differentiate into osteoblasts. Upon transplantation in vivo, CD146
? cells generate bone (CD146 -osteoblasts) and self-renew into CD146
? reticular cells lining the sinusoids, demonstrating that they are functional osteoprogenitors [59] . [18, 27] . Furthermore, short-term ablation of CAR cells in vivo impairs both the osteogenic and the adipogenic differentiation potential of BM cells [27] . Interestingly, Osx-expressing osteoprogenitors have recently been demonstrated to have adipogenic potential as well [62] . Taken together, perivascular mesenchymal progenitors with at least osteogenic and adipogenic potential play an important role in supporting B-lymphocyte differentiation. Two recent studies have confirmed the importance of CXCL12 production by mesenchymal cells and osteoprogenitors but not mature osteoblasts in supporting BM B-lymphoid development [56, 57] . Deletion of CXCL12 in Prx1-expressing mesenchymal progenitors or in Osx-or Col2.3-expressing osteoprogenitors, but not in osteocalcin-expressing mature osteoblasts, leads to depletion of early lymphoid progenitors, with a particular reduction in committed B-lineage progenitors [56, 57] . CD146
? reticular cells produce large amounts of CXCL12 in humans and rodents, can establish a hematopoietic niche upon transplantation, and have been shown to sustain primitive hematopoietic stem and progenitor cells (HSPCs) in vitro through cell-to-cell contact [63] . Taken together, these results demonstrate that perivascular mesenchymal progenitors with osteogenic (and possibly adipogenic) potential are an important source of CXCL12 in the hematopoietic, and specifically B lymphocyte, BM niche.
IL-7-expressing stromal cells, while distinct from CXCL12
? cells, have also been localized to the perivascular space [2, 19] . While IL-7 has not been specifically deleted from osteoblast-lineage cells, the targeted overexpression of human IL-7 to maturing osteoblasts can rescue the osteopenia and B-cell development of IL-7 KO mice, without interfering with T lymphopoiesis [64] .
G s a Signaling in Osteoblast Progenitors is Required for Production of IL-7 and Support of B Lymphopoiesis
Signaling mediated by the parathyroid hormone (PTH)/ PTH-related peptide receptor (PPR) in osteoblasts is an important regulator of the HSC niche [60] . Expression of both CXCL12 and IL-7 is increased in response to PTH stimulation by its actions on PPR [44, 60, 61] . When stimulated with PTH in vitro, calvarial osteoblasts showed marked increases in CXCL12 and IL-7 levels and were able to support B-lymphoid commitment and sustain B-cell differentiation from the earliest B-cell progenitors to the generation of mature IgM ? B cells. Of note, this inductive effect is not shared by adipocytes or endothelial cells [44] .
The PPR is a G protein-coupled receptor, and the G s a subunit of the heterotrimeric G s protein is a major downstream mediator of PPR signaling [65] . We have demonstrated that ablation of G s a early in the osteoblast lineage, in Osx-expressing osteoprogenitors (G s a OsxKO mice), leads to severe osteoporosis with a dramatic reduction in trabecular bone [66, 67] . Notably, G s a OsxKO mice exhibit impaired B lymphopoiesis with a dramatic reduction in B-cell precursors. There is a specific block in the transition from pro-B to pre-B cells, whereas prepro-B cells are unaffected. This transition to pre-B cells is dependent upon IL-7, and IL-7 mRNA levels were significantly reduced in osteoprogenitors from G s a OsxKO mice. In contrast, and consistent with the unchanged frequency of prepro-B cells, CXCL12 mRNA levels were not altered. Moreover, the stage-specific differentiation block could be rescued in G s a OsxKO mice with exogenous treatment of IL-7, and transplantation of KO BM cells into a wild-type host restored the hematopoietic phenotype, confirming the microenvironmental defect in G s a OsxKO mice [66] . While ablation of G s a in osteoprogenitors leads to impaired B-cell development, deletion of G s a in terminally differentiated osteocytes does not affect B lymphopoiesis despite an osteopenic phenotype with reduced osteoblast numbers [66, 68] . Instead, there is a dramatic increase in myeloid cells, mediated by production of granulocyte colony-stimulating factor (G-CSF) by osteocytes [68] . These results again highlight the importance of osteoprogenitors specifically in regulating BM B lymphopoiesis.
Stromal cells with osteogenic capacity and perivascular location expressing CXCL12, IL-7, CD146, Osx, and galectin-1 have therefore been implicated in regulating various stages of B-cell precursor differentiation within the BM. How these cellular subsets overlap and differ remains to be determined by careful studies comparing these populations (Fig. 1) [2, 55, 69, 70] . In contrast, the majority of Gal-1-expressing cells are VCAM1 -, PDGFRa -, and CD31 ? , indicating that these cells constitute a different stromal cell subset [19] . Of note, VCAM-1, together with its ligand VLA-4, has been described to be involved in the maintenance of HSCs in their quiescent state inside their niche. Tokoyoda et al. [2] found that CXCL12 induces a significant increase in adhesion of prepro-B cells, but not pro-B or pre-B, to VCAM-1. This suggests that CXCL12 acts selectively on prepro-B cells to increase the adhesiveness of VLA-4 ligand through the control of the integrin a4, which has been shown to be essential for early B lymphopoiesis in BM [71] .
Additional Animal Models of Impaired Osteoblastic Regulation of B Lymphopoiesis
Recently, additional studies have noted impaired B lymphopoiesis in the setting of an abnormal bone microenvironment, confirming the crucial role of the osteoblast lineage in the B-lymphocyte niche. For example, an impaired B-lymphocyte niche can result from altering the balance between bone formation and bone resorption. Defective B-lymphocyte differentiation has been identified in various mouse models of impaired osteoclastic resorption or osteopetrosis [72] [73] [74] [75] [76] . Osteopetrotic oc/oc mice exhibit a block at the pro-B to pre-B cell transition associated with reduced levels of IL-7; this phenotype can be partly reversed by exogenous IL-7 or restoration of osteoclast function [77, 78] . Treatment with zoledronic acid (ZA), a potent bisphosphonate, to inhibit osteoclast activity also results in an osteopetrotic phenotype with increased bone mass. In response to ZA treatment, the number of B cells is decreased by 50 % in the BM. The reduction in B lymphocytes affected all B-cell subsets from the prepro-B stage but was restricted to BM and was not due to a direct effect of ZA on B lymphocytes or osteoblast/stromal cells [79] . Osteoclastic resorption plays an important role in the recruitment of mesenchymal and osteoblast progenitors [80] , and indeed, in the absence of functioning osteoclasts there is a significant reduction in osteoprogenitors as determined by the colony forming unit-alkaline phosphatase assay. In keeping with osteoprogenitors as a major source of CXCL12 and IL-7 in the hematopoietic niche, the mRNA levels of CXCL12 and IL-7 were dramatically reduced in BM of ZA-treated mice [79] .
In a different model of high bone mass, sclerostin (SOST) KO mice exhibit a marked reduction of B lymphocytes [81] . SOST is a secreted inhibitor of canonical Wnt signaling, primarily expressed by mature osteocytes, and acts on osteoblasts as a negative regulator of bone growth [82, 83] . Mice with deletion of the SOST coding region display highly mineralized bone due to increased osteoblast activity without altered osteoclast activity [84] . Despite the high bone mass and increased activation of osteoblasts, SOST KO mice display a specific reduction in all B-cell stages but not in HSCs or other hematopoietic progenitor populations in the BM. In this case the significant decline of all committed B-cell developmental stages was associated with increased apoptosis at the precursor, immature, and recirculating B-cell stages, rather than with impaired differentiation [81] . Whether osteoprogenitors are specifically implicated has not been investigated. The effects of SOST ablation on osteoprogenitors remain to be characterized. Perhaps in the presence of a hypermineralized bone mainly mature osteoblasts are expanded, while early mesenchymal stromal cells or osteoprogenitor populations might be deficient. The reduction in CXCL12 mRNA levels in stromal cells of SOST KO mice gives support to this idea. Alternatively, Wnt signaling restrains CXCL12 expression in BM stromal cells in vitro, so perhaps overactive Wnt signaling in stromal cells in the absence of SOST results in a reduction of CXCL12 to levels that are not conducive for B-cell survival [85] .
A Role for Macrophages in the Osteoblastic B-Lymphocyte Niche
In addition to direct interactions between B-lymphocyte precursors and osteoblast-lineage cells, several recent studies have highlighted a role for macrophages in regulating the hematopoietic niche via osteoblasts. Tissue-resident macrophages, termed ''osteomacs,'' can be identified in close association with areas of bone remodeling and are required for optimal bone-forming activity in vitro and in vivo [86] . Mobilization of hematopoietic stem/progenitor cells by G-CSF is associated with suppression of endosteal bone formation and decreased expression of ? osteoprogenitors can produce both CXCL12 and IL-7; how these subsets differ or overlap and whether they give rise to mature osteoblasts lining the bone surface remain to be determined CXCL12 [30, 34] . However, osteoblast-lineage cells do not express G-CSF receptors; instead, the actions of G-CSF on HSPCs and osteoblasts are mediated by macrophages. Several in vivo studies have demonstrated that loss of macrophages negatively affected the growth and/or survival of osteoblasts and allowed egress of HSPCs to the bloodstream [33] [34] [35] . In addition, mobilizing doses of G-CSF impaired medullary B lymphopoiesis, with reduction of all B-cell precursors as well as immature and mature B lymphocytes and increased levels of apoptotic B cells in BM [87] . Since B lymphocytes and their precursors do not express the G-CSF receptor, this phenomenon may also reflect a role for macrophages in the regulation of B lymphopoiesis by cells of the osteoblast lineage.
Conclusions
In summary, the complexity of the cross-talk between cells involved in bone homeostasis and hematopoiesis has become increasingly apparent, especially in the regulation of BM B-lymphocyte development. Further studies are needed to characterize different stromal populations involved in order to better understand their contribution to the generation of unique BM niches, their roles in the cross-talk with hematopoietic cells, and the temporal and spatial mechanisms by which they can regulate the cell cycle and differentiation program of hematopoietic cells. In particular, a clearer understanding of the interactions between hematopoietic and mesenchymal cell populations at specific stages of differentiation is needed. 
